Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 708 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Ocular Dryness Clear all
Completed Phase 2 Interventional Results available

Study to Assess Safety and Efficacy of Filgotinib, Lanraplenib and Tirabrutinib in Adults With Active Sjogren's Syndrome

NCT03100942
View directory record Official record
Conditions
Sjogren's Syndrome
Interventions
Lanraplenib, Filgotinib, Tirabrutinib, Lanraplenib placebo, Filgotinib placebo, Tirabrutinib placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
152 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
34
States / cities
Mesa, Arizona • Phoenix, Arizona • Covina, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2020 · Synced Jul 22, 2026, 11:02 AM EDT
Terminated Not applicable Interventional

Smartphone Mindfulness Meditation for Patients With Rheumatic Diseases

NCT03937856
View directory record Official record
Conditions
Inflammatory Arthritis, Scleroderma, Myositis, Sjogren's Syndrome, Systemic Lupus Erythematosus, Vasculitis
Interventions
Calm- Mindfulness Meditation smartphone application
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Early Phase 1 Interventional

The Effects and Safety of 5% Lifitegrast Ophthalmic Solution in Subjects With Dry Eye Disease in Ocular Graft-versus-Host Disease

NCT04792580
View directory record Official record
Conditions
Graft-versus-host-disease, Ocular Graft-versus-host Disease
Interventions
Lifitegrast 5% Ophthalmic Solution, Placebo
Drug
Lead sponsor
Richard W Yee, MD
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Bellaire, Texas
Source: ClinicalTrials.gov public record
Updated Jul 14, 2024 · Synced Jul 22, 2026, 11:02 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Efficacy and Safety of Meibomian Gland Dysfunction and Dry Eye With an LED Blue Treatment Device

NCT03788486
View directory record Official record
Conditions
Meibomian Gland Dysfunction
Interventions
2-3 Joule LED blue light device
Device
Lead sponsor
Toyos Clinic
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Germantown, Tennessee • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 7, 2020 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of ECF843 vs Vehicle in Subjects With Dry Eye Disease

NCT04391894
View directory record Official record
Conditions
Dry Eye
Interventions
ECF843, ECF843 vehicle
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
718 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
52
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 46 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2025 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 2Phase 3 Interventional

Study of TOP1630 for Dry Eye Syndrome

NCT03833388
View directory record Official record
Conditions
Dry Eye Syndrome
Interventions
TOP1630 0.1% Ophthalmic Solution TID OU, Placebo to TOP1630 0.1% Ophthalmic Solution TID OU
Drug
Lead sponsor
Topivert Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
4
States / cities
Lewiston, Maine • Andover, Massachusetts • Raynham, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2019 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety and Tolerability of NOV03 (Perfluorohexyloctane) in Subjects Who Completed Trial NVU-003 (Kalahari Study)

NCT04140227
View directory record Official record
Conditions
Dry Eye Disease (DED)
Interventions
NOV03
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
28
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Glendale, California + 24 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2024 · Synced Jul 22, 2026, 11:02 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Photobiomodulation & Ketogenic Diet for Treatment of Mid-periphery Retinal Disorders for Alzheimer's Disease Prevention

NCT03859245
View directory record Official record
Conditions
Diabetic Retinopathy (DR), Age-related Macular Degeneration (AMD), Mid-peripheral Drusen Formation, Diabetic Macular Edema (DME)
Interventions
Photobiomodulation, Ketogenic diet
Behavioral
Lead sponsor
Bristlecone Health, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Eagan, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 3, 2019 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 2Phase 3 Interventional

Safety and Efficacy Assessment Treatment Trials of Emixustat Hydrochloride

NCT01802866
View directory record Official record
Conditions
Geographic Atrophy
Interventions
ACU-4429, Placebo
Drug
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
55 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Clinical Evaluation of a Multidose Preservative-free Lubricating Eye Drops Contained in Novelia® Eye Dropper in Non-Contact Lens Wearing Patients

NCT05661851
View directory record Official record
Conditions
Dry Eye
Interventions
Investigational Lubricating Eye Drop in a Novelia® bottle, Blink® Tears eye Drops
Drug
Lead sponsor
Johnson & Johnson Vision Care, Inc.
Industry
Eligibility
18 Years to 69 Years
Enrollment
121 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
8
States / cities
Jacksonville, Florida • Pittsburg, Kansas • Medina, Minnesota + 4 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2025 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Not applicable Interventional

Corneal Epithelial Stem Cells and Dry Eye Disease

NCT03302273
View directory record Official record
Conditions
Dry Eye Syndromes, Dry Eye, Ocular Inflammation, Ocular Surface Disease, Ocular Discomfort, Blepharitis
Interventions
Corneal Epithelial Stem Cell Transplant
Other
Lead sponsor
Sloan W. Rush, MD
Other
Eligibility
18 Years to 100 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Amarillo, Texas
Source: ClinicalTrials.gov public record
Updated Apr 20, 2022 · Synced Jul 22, 2026, 11:02 AM EDT
Withdrawn Phase 2 Interventional

Study to Evaluate Sub-retinal Transplantation of Retinal Pigmented Epithelial Cells in Patients With Dry AMD

NCT02563782
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Sub-retinal transplantation of MA09-hRPE cells, tacrolimus and mycophenolate mofetil, Placebo tacrolimus and mycophenolate mofetil, Sham Surgery
Biological · Drug · Procedure
Lead sponsor
Astellas Institute for Regenerative Medicine
Industry
Eligibility
50 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 25, 2017 · Synced Jul 22, 2026, 11:02 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effects of ASP5502 in Healthy Adults and Adults With Primary Sjögren's Syndrome

NCT06544642
View directory record Official record
Conditions
Healthy Volunteers, Sjögren's Syndrome
Interventions
ASP5502, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Not applicable Interventional

Ocular Surface Disease Changes After iStent or iStent Inject Implantation With Phacoemulsification

NCT04452279
View directory record Official record
Conditions
Ocular Surface Disease, Glaucoma, Open-Angle
Interventions
iStent or iStent inject implantation with concomitant cataract surgery
Device
Lead sponsor
Vance Thompson Vision
Other
Eligibility
22 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Sioux Falls, South Dakota
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Jul 22, 2026, 11:02 AM EDT
Active, not recruiting Not applicable Interventional

PRIMA US-Feasibility Study in Atrophic Dry AMD

NCT03392324
View directory record Official record
Conditions
Dry Age-related Macular Degeneration
Interventions
PRIMA
Device
Lead sponsor
Science Corporation
Industry
Eligibility
60 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2026
U.S. locations
3
States / cities
Palo Alto, California • Miami, Florida • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 2 Interventional

Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy

NCT01002950
View directory record Official record
Conditions
Dry Age-related Macular Degeneration, Geographic Atrophy
Interventions
ACU-4429, Matching placebo
Drug
Lead sponsor
Kubota Vision Inc.
Industry
Eligibility
Not listed
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
12
States / cities
Phoenix, Arizona • Beverly Hills, California • Daytona Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Jul 22, 2026, 11:02 AM EDT
Active, not recruiting Phase 3 Interventional

A Safety and Efficacy Study of Dazodalibep in Participants With Sjögren's Syndrome (SS) With Moderate-to-Severe Symptom State

NCT06245408
View directory record Official record
Conditions
Sjögren's Syndrome (SS)
Interventions
Dazodalibep, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
434 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
41
States / cities
Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 37 more
Source: ClinicalTrials.gov public record
Updated Jan 7, 2026 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 4 Interventional

CEQUA for Sjogren's Syndrome Dry Eye

NCT04835623
View directory record Official record
Conditions
Dry Eye, Dry Eye Syndromes, Sjogren's Syndrome
Interventions
Cyclosporine 0.09% Ophthalmic Solution
Drug
Lead sponsor
Center for Ophthalmic and Vision Research, LLC
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Manhattan, New York
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Jul 22, 2026, 11:02 AM EDT
Recruiting Phase 2 Interventional

A Phase IIb Randomized, Multicenter Trial of Subretinal CPCB-RPE1 in Advanced Dry AMD (Geographic Atrophy)

NCT06557460
View directory record Official record
Conditions
Dry Age-related Macular Degeneration, Geographic Atrophy
Interventions
Surgical implantation of the CPCB-RPE1 implant
Device
Lead sponsor
Regenerative Patch Technologies, LLC
Industry
Eligibility
55 Years to 90 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2040
U.S. locations
5
States / cities
Beverly Hills, California • Huntington Beach, California • Los Angeles, California + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Dose Ranging Study to Assess the Efficacy and Safety of Voclosporin Ophthalmic Solution in Subjects With Dry Eye Syndrome

NCT04147650
View directory record Official record
Conditions
Dry Eye Syndrome, Keratoconjunctivitis Sicca
Interventions
0.05% Voclosporin Ophthalmic Solution (VOS), 0.10% VOS, 0.20% VOS, Vehicle Ophthalmic Solution
Drug
Lead sponsor
Aurinia Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
9
States / cities
Newport Beach, California • Colorado Springs, Colorado • Louisville, Kentucky + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 9, 2021 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Not applicable Interventional

Tear Lipid Layer Thickness Assessments With Perfluorohexyloctane Eye Drops

NCT05288582
View directory record Official record
Conditions
Dry Eye
Interventions
NovaTears
Device
Lead sponsor
Ohio State University
Other
Eligibility
30 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 7, 2023 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Not applicable Interventional Results available

Efficacy of IPL Treatment of Dry Eye and Ocular Rosacea

NCT03194698
View directory record Official record
Conditions
Ocular Rosacea, Dry Eye
Interventions
Intense Pulsed Light Treatment (IPL), Meibomian Gland Expression
Device · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 100 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 2, 2020 · Synced Jul 22, 2026, 11:02 AM EDT
Completed Not applicable Interventional Results available

to Evaluate the Effectiveness and Safety of the Tixel® , VS LipiFlow® in the Treatment of Meibomian Gland Dysfunction

NCT05162261
View directory record Official record
Conditions
Meibomian Gland Dysfunction, Dry Eye Syndromes, Dry Eye
Interventions
Tixel C, LipiFlow
Device
Lead sponsor
Novoxel Ltd.
Industry
Eligibility
22 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
5
States / cities
La Jolla, California • Newport Beach, California • Kansas City, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2025 · Synced Jul 22, 2026, 11:02 AM EDT
Completed No phase listed Observational

Digital Photography to Evaluate Dry Eye

NCT00073099
View directory record Official record
Conditions
Eye Disease
Interventions
Not listed
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
2 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 22, 2026, 11:02 AM EDT